Magnesium - A profibrillatory or antifibrillatory drug depending on plasma concentration, heart rate and myocardial perfusion

Acta Anaesthesiologica Scandinavica

Volumn 41, Issue 4, 1997, Pages 516-523

  Aupetit, J F ^a   Freysz, M ^b   Faucon, G ^c   Loufoua Moundanga, J ^c   Coquelin, H ^a   Timour, Q ^c  

^a CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

^b GENERAL HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

Magnesium: antifibrillatory action; Myocardial ischemia; Profibrillatory action; Ventricular fibrillation

Indexed keywords

MAGNESIUM SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE POTENTIAL; HEART PERFUSION; HEART RATE; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0030935466     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1997.tb04734.x     Document Type: Article

References (34)

1. McLean R. Magnesium and its therapeutic uses : a review. Am J Med 1994: 96: 63-76.
2. Iseri LT, Allen BJ, Brodsky A. Magnesium therapy of cardiac arrhythmias in critical care medicine. Magnesium 1989: 8: 299-306.
3. Hindricks G, Kottkamp H, Haverkamp W, Shenasa M, Shenasa H, Borggrefe M, et al. Magnesium-electrophysiological effects, antiarrhythmic properties and clinical implications. In : Breithardt G, Borggrefe M, Camm J, Shenesa M, eds. Antiarrhythmic drugs. Mechanisms of antiarrhythmic and proarrhythmic actions. Berlin: Springer, 1995: 363-390.
4. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, et al. Treatment of torsades de pointes with magnesium sulfate. Circulation 1988: 77: 392-397.
5. Keren A, Tzivoni D. Magnesium therapy in ventricular arrhythmias. Pace 1990: 13: 937-945.
6. Toivonen LK, Leinonen H. Limited effects of magnesium sulfate on torsades de pointes ventricular tachycardia. Int J Cardiol 1986: 12: 260-262.
7. Cohen L, Kitzes R. Magnesium sulfate and digitalis toxic arrhythmias. J Am Med Assoc 1983: 249: 2808-2810.
8. French JH, Thomas RG, Siskind AP, Brodsky M, Iseri LT, California O. Magnesium therapy in massive digitalis intoxication. Ann Emerg Med 1984: 13: 562-566.
9. Allen BT, Brodsky MA, Caparell EV, Luckett CR, Iseri LT. Magnesium sulfate therapy for sustained monomorphic ventricular tachycardia. Am J Cardiol 1989: 64: 1202-1204.
10. Hilton TC, Fredman C, Holt DJ, Bjerregaard P, Ira GH, Janosik DL. Electro-physiologic and antiarrhythmic effects of magnesium in patients with inducible ventricular tachycardia. Clin Cardiol 1992: 15: 176-180.
11. ISIS Collaborative Group (ISIS-4). Randomized study of intravenous magnesium in over 50 000 patients with suspected acute myocardial infarction. Circulation 1993: 88 (Suppl. 10): 1-292.
12. Horner SM. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction. Circulation 1992: 86: 774-779.
13. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulfate in suspected acute myocardial infarction : results of the second Leicester Intravenous Myocardial Infarction Trial (LIMIT-2). Lancet 1992: 339: 1553-1558.
14. Aupetit JF, Timour Q, Chevrel G, Loufoua-Moundanga J, Omar S, Faucon G. Attenuation of the ischaemia-induced fall of electrical ventricular fibrillation threshold by a calcium antagonist, diltiazem. Naunyn-Schmiedeberg's Arch Pharmacol 1993: 348: 509-514.
15. Aupetit JF, Timour Q, Loufoua-Moundanga J, Barral-Cadière L, Lopez M, Freysz M, et al. Profibrillatory effects of lidocaine in the acutely ischaemic porcine heart. J Cardiovasc Pharmacol 1995: 25: 810-816.
16. Wit AL, Weiss MB, Berkowitz WD, Rosen KM, Steiner C, Damato AN. Pattern of atrioventricular conduction in the human heart. Circ Res 1970: 27: 345-359.
17. James RGG, Arnold JMO, Allen JD, Pantridge JF, Shanks RG. The effect of heart rate, myocardial ischemia and vagal stimulaton on the threshold for ventricular fibrillation. Circulation 1977: 55: 311-317.
18. Aupetit JF, Timour Q, Loufoua-Moundanga J, Omar S, Chevrel G, Faucon G. Vulnerability to ventricular fibrillation related to ischaemia. Comparison of the acute effects of b-blockers and calcium antagonists. Arch Int Pharmacodyn 1994: 327: 25-39.
19. + increase and noradrenaline release as a possible cause of early arrhythmias following acute coronary occlusion in pigs. J Mol Cell Cardiol 1980: 12: 579-593.
20. Gettes LS, Cascio WE, Johnson T, Fleet WF. Local myocardial biochemical and ionic alterations during myocardial ischaemia and reperfusion. Drugs 1991: 42 (Suppl. 1): 7-13.
21. Heijnis JB, Coronel R, Van Zwieten PA. The effects of calcium antagonists on extracellular potassium accumulation during global ischaemia in isolated perfused rat hearts. Cardiovasc Drugs Ther 1991: 5: 1035-1041.
22. Abraham AS, Rosenmann D, Meshulam Z, Zion MM, Eylath U. Serum, lymphocyte and erythrocyte potassium, magnesium and calcium concentrations and their relation to tachyarrhythmias in patients with acute myocardial infarction. Am J Med 1986: 81: 983-988.
23. Abraham AS. Treatment of patients with acute myocardial infarction with intravenous magnesium. Magnesium Trace Elem 1990: 9: 177-185.
24. Reinhart RA, Marx JJ, Broste SK, Haas RG. Myocardial magnesium: relation to laboratory and clinical variables in patients undergoing cardiac surgery. J Am Coll Cardiol 1991: 17: 651-656.
25. Watanabe Y, Dreifus LS. Electrophysiological effects of potassium and interactions with magnesium. Cardiovasc Res 1972: 6: 79-88.
26. Kraft LF, Katholi RE, Woods WT, James TN. Attenuation by magnesium of the electrophysiologic effects of hyperkalemia on human and canine heart cells. Am J Cardiol 1980: 45: 1189-1195.
27. Woods WT Jr, Chapman GD. Preservation of resting potential by magnesium in hypoxic canine cardiac cells. Am J Cardiol 1984: 53: 528-530.
28. Downar E, Janse MJ, Durrer D. The effect of acute coronary occlusion on subepicardial transmembrane potential in the intact porcine heart. Circulation 1977: 56: 217-224.
29. Blake K, Clusin WT. Effect of diltiazem on ischaemic myocardial depolarization and extracelular potassium accumulation. Eur J Pharmacol 1986: 127: 261-265.
30. De Mello WC, Hoffman BF. Potassium ions and electrical activity of specialized cardiac fibers. Am J Physiol 1960: 199: 1125-1130.
31. Fisch C. Relation of electrolyte disturbances to cardiac arrhythmias. Circulation 1973: 47: 408-419.
32. Lang J, Timour Chah Q, Charve P, Aupetit JF, El Chebly M, Faucon G. Role of calcium in the rate-dependent depression of atrioventricular nodal conduction in the dog heart under vagal influence. Int J Cardiol 1987: 15: 65-76.
33. Gettes LS, Surawicz B, Shine JC. Effect of high K, low K and quinidine on QRS duration and ventricular action potential. Am J Physiol 1962: 203: 1135-1141.
34. Timour Chah Q, Braly G, Bouzouita K, Faucon G. Effects of hypokalemia on the various parts of the conduction system of the dog heart in situ. Naunyn-Schmiedeberg's Arch Pharmacol 1982: 319: 178-183.